On February 17, 2021, the FDA approved a supplemental application for Tecentriq (atezolizumab), indicating an expansion of its approved efficacy. This approval was granted to Genentech Inc., the sponsor of the application.
What this means
The supplemental FDA approval for atezolizumab (Tecentriq) on February 17, 2021, signifies an expansion of its demonstrated efficacy. This type of approval is granted when new clinical data supports an additional or refined use for the drug, potentially allowing it to be prescribed for a new indication, a different patient population, or under modified conditions where its benefits have been further established. For healthcare providers, this means the prescribing information for Tecentriq has been updated to reflect these new efficacy findings. It is crucial for clinicians to review the full updated label to understand the specific details of this expanded efficacy, including any new patient populations, dosing recommendations, or safety considerations. This update aims to provide more treatment options for patients who may benefit from atezolizumab.
Source
This information is based on a supplemental application approval by the U.S. Food and Drug Administration (FDA) for Tecentriq (atezolizumab), dated February 17, 2021. The details are available on the FDA's website, accessdata.fda.gov, under application number BLA761034.